TL;DR
Researchers conducted the largest multi-ancestry genome-wide association study (GWAS) of prostate-specific antigen (PSA) levels to date, involving over 392,000 men. By identifying 447 genetic variants—nearly 300 of which are novel—the team developed a polygenic risk score (PRS) that significantly improves the accuracy of PSA-based prostate cancer screening across diverse populations, potentially reducing unnecessary biopsies.
What Problem Does This Paper Address?
Prostate-specific antigen (PSA) is the primary biomarker used to screen for prostate cancer. However, it is a "noisy" signal. PSA levels are influenced by many non-cancerous factors, including age, prostate volume, inflammation, and an individual's baseline genetic makeup.
This noise leads to a major clinical challenge: many men with naturally high PSA levels undergo invasive, unnecessary biopsies (overdiagnosis), while others with naturally low levels might have their cancer missed. Furthermore, most existing genetic studies on PSA have focused on men of European ancestry, leaving a significant performance gap in polygenic risk scores (PRSs) for men of African, Hispanic/Latino, and Asian descent. This paper aims to "de-noise" PSA levels by accounting for genetic variation across a diverse global population.
Methods
The study followed a multi-stage GWAS pipeline:
- Discovery: A multi-ancestry analysis of log-transformed PSA levels in ~297,000 men using mJAM (multi-ancestry Joint Association Mapping), which utilizes population-specific linkage disequilibrium (LD) reference panels to account for different genetic architectures.
- Replication: Findings were tested in an independent cohort of ~96,000 men.
- Meta-analysis: The teams combined discovery and replication data to identify the final set of associated variants.
- PRS Construction: They used PRS-CSx, a Bayesian method that integrates GWAS summary statistics from multiple ancestries to improve cross-population prediction.
- Clinical Modeling: The researchers calculated "genetically adjusted PSA" by dividing a person's measured PSA by their genetic predisposition factor. They then evaluated how this adjustment would have changed biopsy recommendations in real-world cohorts.
Datasets
The study leveraged several massive datasets:
- Million Veteran Program (MVP): Provided 96.5% of the discovery cohort.
- Replication Cohorts: Included data from previous studies (Kachuri et al. 2023).
- Validation Cohorts: Out-of-sample evaluation was performed using the GERA cohort, the SELECT and PCPT clinical trials, and the All of Us (AOU) research program.
- Ancestry Breakdown: The total sample included 297,166 men of European ancestry, 61,745 of African ancestry, 26,644 Hispanic/Latino men, and 6,967 men of Asian ancestry.
Key Insights and Ideas
- Diversity is a Performance Multiplier: By including a higher proportion of underrepresented populations, the researchers more than doubled the predictive power of PRSs for men of African ancestry compared to previous models.
- The "De-noising" Effect: Genetically adjusting PSA levels helps distinguish between men who have high PSA because of their genes versus those who have high PSA because of aggressive cancer.
- Age Matters: The study found that the variance in PSA explained by genetics decreases as men get older. This suggests that environmental factors or cumulative prostate health issues (like BPH) begin to outweigh germline genetics in older age groups.
- Functional Links: Many of the identified variants were linked to genes involved in hormone signaling (like the androgen receptor AR) and even male fertility (like CFTR and LMTK2), providing new biological leads for prostate physiology.
Key Results
- Variant Discovery: Identified 447 independent variants associated with PSA levels, 295 of which were previously unknown.
- Variance Explained: The new PRS explained a substantial portion of PSA variation: 16.9% in European, 18.6% in Hispanic/Latino, 15.3% in Asian, and 9.5% in African ancestries.
- Biopsy Reclassification: In the GERA cohort, using genetically adjusted PSA resulted in a 7.4% net improvement in reclassifying healthy European controls (meaning they would have avoided an unnecessary biopsy).
- Aggressive Cancer Detection: Higher genetic scores for PSA were inversely associated with aggressive disease (Gleason score ≥7). This confirms that men with high "genetic PSA" are often biopsied for the wrong reasons, while those with low "genetic PSA" might have aggressive cancers that stay "hidden" below standard clinical thresholds.
Limitations and Future Work
- African Ancestry Gap: While prediction improved significantly for men of African ancestry, the variance explained (9.5%) still lags behind other groups, likely due to the smaller discovery sample size and higher genetic diversity in this population.
- Missing Clinical Data: Many cohorts lacked data on prostate volume and Benign Prostatic Hyperplasia (BPH), both of which are major non-genetic drivers of PSA levels.
- Screening Bias: The authors acknowledge that GWAS of PSA can be influenced by "screening bias"—men with higher genetic PSA are more likely to be screened and diagnosed, which can complicate the relationship between PSA variants and cancer risk.
- Future Directions: The authors suggest that future work should focus on even larger diverse cohorts and the development of PRSs that specifically target different constituents of total PSA (like free vs. bound PSA).
Summary updated